Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,569,724
  • Shares Outstanding, K 50,932
  • Annual Sales, $ 276,260 K
  • Annual Income, $ 16,520 K
  • EBIT $ 11 M
  • EBITDA $ 23 M
  • 60-Month Beta 1.22
  • Price/Sales 5.80
  • Price/Cash Flow 56.60
  • Price/Book 4.48

Options Overview Details

View History
  • Implied Volatility 72.32% (+5.21%)
  • Historical Volatility 41.31%
  • IV Percentile 68%
  • IV Rank 50.94%
  • IV High 95.56% on 04/08/25
  • IV Low 48.19% on 10/20/25
  • Expected Move (DTE 20) 4.49 (15.30%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 1,338
  • Put/Call OI Ratio 1.97
  • Today's Open Interest 22,926
  • Open Int (30-Day) 3,243
  • Expected Range 24.85 to 33.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.16
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +39.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.95 +1.35%
on 03/27/26
36.10 -18.73%
on 03/02/26
-6.34 (-17.77%)
since 02/27/26
3-Month
28.95 +1.35%
on 03/27/26
41.65 -29.56%
on 01/08/26
-8.32 (-22.09%)
since 12/26/25
52-Week
28.95 +1.35%
on 03/27/26
46.10 -36.35%
on 03/28/25
-16.73 (-36.31%)
since 03/27/25

Most Recent Stories

More News
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of...

VCEL : 29.34 (-4.80%)
Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 29.34 (-4.80%)
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record...

VCEL : 29.34 (-4.80%)
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 29.34 (-4.80%)
Vericel Announces Preliminary 2025 Financial Results and Business Updates

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE...

VCEL : 29.34 (-4.80%)
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 29.34 (-4.80%)
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 29.34 (-4.80%)
Vericel Reports Third Quarter 2025 Financial Results

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating...

VCEL : 29.34 (-4.80%)
Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025

CAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 29.34 (-4.80%)
Leerink Partners Keeps Their Buy Rating on Vericel (VCEL)

In a report released on October 14, Mike Kratky from Leerink Partners maintained a Buy rating on Vericel, with a price target of $48.00. The company’s shares closed yesterday at $33.59.Elevate Your Investing...

VCEL : 29.34 (-4.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 32.03
2nd Resistance Point 31.33
1st Resistance Point 30.34
Last Price 29.34
1st Support Level 28.65
2nd Support Level 27.95
3rd Support Level 26.96

See More

52-Week High 46.10
Fibonacci 61.8% 39.55
Fibonacci 50% 37.52
Fibonacci 38.2% 35.50
Last Price 29.34
52-Week Low 28.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.